IVACC Share Price Performance
SEK 0.63
-0.42 (-40.19%)
Price SEK 0.63
Share Pricen/a
Intervacc AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
IVACC Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Intervacc AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 14, 2026
- -0.24
- -57.18%
- -402.32%
- 0.03%
About IVACC
- Founded
- 1983
- Employees
- 15
- CEO
- WebsiteView website
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.
